APOE and Alzheimer disease: Finally, two different doses of CAD106 (150 and 450 mg), with and without adjuvants, were trialled in a 90-week, randomised, double-blind, placebo-controlled phase IIb study on a total of 121 patients with mild AD, most of them (101/121) being APOE ε4 carriers [47].